Randomized double-blind study of flunarizine versus placebo in patients with chronic cerebrovascular disorders.

Abstract

Chronic cerebrovascular disorders (CCVD), as defined by the 1980 Ad Hoc Committee in Paris, constitute both clinically and pathogenetically an extremely complex entity, characterized by a protean symptom pattern. The effects of a daily dose of 10 mg flunarizine orally on CCVD have been evaluated with a neuropsychological methodology during a three-month treatment period in a randomized double-blind study compared with a placebo. The results confirmed the effectiveness of the drug in the improvement of neurological, amnesic, attentive and behavioural symptoms, without evident side-effects even after a long-term treatment.

• Authors: A Agnoli, V Manna, N Martucci, M Fioravanti, F Ferromilone, A Cananzi, G D'Andrea, A De Rosa, R Vizioli, E Sinforiani
• Journal: International journal of clinical pharmacology research (Int J Clin Pharmacol Res) Vol. 8 Issue 3 Pg. 189-97 ( 1988) ISSN: 0251-1649 [Print] Switzerland
• PMID: 3042644 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)

Chemical References

• Flunarizine

Topics

• Adult
• Aged
• Cerebrovascular Disorders (drug therapy)
• Clinical Trials as Topic
• Double-Blind Method
• Female
• Flunarizine (adverse effects, therapeutic use)
• Humans
• Male
• Middle Aged
• Random Allocation